Post-operative radiation therapy to the surgical cavity with standard fractionation in patients with brain metastases
- PMID: 32286375
- PMCID: PMC7156661
- DOI: 10.1038/s41598-020-63158-6
Post-operative radiation therapy to the surgical cavity with standard fractionation in patients with brain metastases
Abstract
The paradigm for post-operative cavity radiation therapy has shifted to more targeted, less morbid approaches. Single-fraction or hypofractionated radiation therapy is a common approach to treating the postoperative cavity but is associated with a local failure rate 20-40%. We employed an alternative treatment strategy involving fractionated partial brain radiation therapy to the surgical cavity. Patients with brain metastases who underwent radiation treatment 30-42 Gy in 3 Gy/fraction regimens to surgical cavity were retrospectively identified. The 6-month and 12-month freedom from local failure rates were 97.0% and 88.2%. Three patients (7%) experienced local failure at 4, 6, and 22 months. Of these, the histologies were colorectal adenocarcinoma (N = 1) and breast adenocarcinoma (N = 2). The 6-month and 12-month freedom from distant brain metastases rates were 74.1% and 68.8%, respectively, and the 6-month and 12-month overall survival rates were 84.9% and 64.3% respectively. The median overall survival was 39 months, and there were no events of late radionecrosis. Fractionated partial brain irradiation to the surgical cavity of resected brain metastases results in low rates of local failure. This strategy represents an alternative to SRS and WBRT.
Conflict of interest statement
Author J.B. owns stock in company, Advanced Chemotherapy Technologies, which has no relationship to the current work. Author H.S. serves on an Advisory Board for Genentech. Author T.B. declares that he has no conflicts of interest. Author A.N. declares that he has no conflicts of interest. Author J.L. declares that he has no conflicts of interest. Author K.O. received research funding from Merck & Co., Inc. for clinical trials on immune therapy and brain metastases and Elekta for research on a multi-institutional brain metastases consortium.
Figures
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
